RT Journal Article
T1 Onco-Nephrology: Cancer, chemotherapy and kidney.
T2 Onco-Nefrología: cáncer, quimioterapia y riñón.
A1 de Francisco, Angel L M
A1 Macía, Manuel
A1 Alonso, Fabiola
A1 García, Patricia
A1 Gutierrez, Eduardo
A1 Quintana, Luis Fernando
A1 Quiroga, Borja
A1 Torregrosa, Isidro
K1 Chemotherapy
K1 Immunotherapy
K1 Inmunoterapia
K1 Nefropatía y cáncer
K1 Nephropathy and cancer
K1 Onco-Nefrología
K1 Onco-Nephrology
K1 Quimioterapia
AB Chronic kidney disease (CKD), cancer and haematological diseases share areas of reciprocal influence. Cancer can affect the kidney either as glomerular lesions or as a result of the toxic effects of medication or radiation with acute (thrombotic microangiopathy, acute kidney injury, interstitial nephropathies among others) or chronic processes (worsening of CKD after nephrectomy due to renal cancer, interstitial fibrosis, hydroelectrolytic disorders). On the other hand, patients who require renal replacement therapy with dialysis and particularly with kidney transplantation are at high risk of onset of cancer due to the immunosuppression situation that they generate. In addition to conventional chemotherapy, innovative treatments have been developed: target agents against growth factors and their receptor; anti-angiogenic drugs; immunoregulatory proteins; cell cycle regulators; and enzyme inhibitors. Other immunotherapeutic approaches have also been developed, such as vaccines, adoptive cell therapy (CAR T cells) or development of antibodies. All these therapeutic advances will improve the outcomes against cancer and haematological diseases, but they are not free from secondary renal problems. Onco-Nephrology is already an important area for the Spanish Society of Nephrology with a large number of inter-consultations. Nephrologists need a better understanding of rapidly evolving areas of cancer biology and its treatment in order to become valued members of the cancer care team and to provide the best nephrology care possible.
YR 2019
FD 2019-03-29
LK http://hdl.handle.net/10668/13774
UL http://hdl.handle.net/10668/13774
LA en
LA es
DS RISalud
RD Apr 5, 2025